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Detachment or apoptosis of podocytes leads to proteinuria
and glomerulosclerosis. There are no current interventions
for diabetic or non-diabetic glomerular diseases specifically
preventing podocyte apoptosis. Binding of erythropoiesis
stimulating proteins (ESPs) to receptors on
non-hematopoietic cells has been shown to have
anti-apoptotic effects in vitro, in vivo, and in preliminary
human studies. Recently, erythropoietin receptors were
identified on podocytes; therefore, we tested effects of
darbepoetin alfa in preventing podocyte apoptosis. Cultured
immortalized mouse podocytes were treated with low-dose
ultraviolet-C (uv-C) irradiation to induce apoptosis in the
absence or presence of darbepoetin alfa. Apoptosis was
quantified by Hoechst staining and by caspase 3 cleavage
assessed by Western blots. Pretreatment with darbepoetin
alfa significantly reduced podocyte apoptosis with this effect
involving intact Janus family protein kinase-2 (JAK2) and AKT
signaling pathways. Additionally, darbepoetin alfa was found
protective against transforming growth factor-b1 but not
puromycin aminonucleoside induced apoptosis. Mice with
anti-glomerular antibody induced glomerulonephritis had
significantly less proteinuria, glomerulosclerosis, and
podocyte apoptosis when treated with darbepoetin alfa. Our
studies show that treatment of progressive renal diseases
characterized by podocyte apoptosis with ESPs may be
beneficial in slowing progression of chronic kidney disease.
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Primary function of erythropoietin (EPO) is to prevent
apoptosis of developing erythroid precursor cells. Addition-
ally, EPO works synergistically with multiple other growth
factors to promote differentiation and proliferation of these
erythroid progenitor cells.1 Recently, the EPO receptor has
been identified on non-hematopoietic tissues.2,3 Similar to
the effects on the developing erythroid cell, EPO has potent
cell survival effects once it is bound to its tissue receptor.
Toxic and ischemic models of central and peripheral neuronal
injury have shown a profound anti-apoptotic effect for EPO
in cell culture, animal models, and preliminary human
studies.4 EPO exhibits a prosurvival role in models of
myocyte ischemia as well as toxic and hypoxic renal tubular
injury.5 In conjunction with other growth factors, EPO also
plays a role in the proliferation and differentiation of non-
erythroid cell lines such as astrocytes.6 Other erythropoiesis
stimulating proteins (ESPs) and non-hematopoietic derivatives
of EPO, such as asialoEPO7 and carbamylated EPO,8,9 have
demonstrated beneficial effects in non-hematopoietic tissues.
EPO exerts a hematopoietic function by triggering
intracellular phosphorylation events that lead to activation
of prosurvival pathways. The well-defined signaling mechan-
isms associated with erythroid precursor survival are multi-
ple and redundant, culminating in the end point of being
anti-apoptotic. After EPO binds to its receptor, there is
activation of Janus family protein kinase-2 (JAK2), and
downstream signaling cascades including STAT5, nuclear
factor-kB, and phosphoinositide-3 kinase with subsequent
phosphorylation of AKT.4 The mechanisms by which EPO or
ESPs are anti-apoptotic in non-hematopoietic tissues are
thought to be similar in some aspects to the erythroid
precursor cell-survival pathways but this has not been
completely elucidated and is potentially cell specific.10
Owing to their quiescent phenotype, podocytes have a
limited ability to perform a controlled re-entry into the
mitotic cell cycle.11 Therefore, when podocytes are reduced in
number following injury, either by shedding of detached
viable podocytes into the urine or apoptosis, they are
typically not replaced. Podocyte loss, experimentally and in
human disease, has been linked to the development of
proteinuria and glomerulosclerosis,12 and is predictive of the
progression of diseases such as diabetes13–16 and IgA
nephropathy.17 Although our group has shown recently that
dexamethasone protects podocytes from apoptosis in vitro,18
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there are no published therapies to prevent podocyte loss in
diabetic or non-diabetic glomerular disease.
Recently, EPO receptors have been identified on podocytes
in fixed tissue,19 raising the possibility that podocytes in vitro
and in vivo can respond to hematopoietic growth factor
stimulation. The purpose of this study was to define the
effects of ESPs on podocytes. Our hypothesis is that ESPs are
prosurvival for podocytes both in vitro and in vivo. Our
results show that the ESP darbepoetin alfa indeed protects
podocytes from apoptosis and in vivo therapy with
darbepoetin alfa results in less proteinuria and glomerulo-
sclerosis in a mouse model of glomerulonephritis.
RESULTS
The erythropoietin receptor is expressed on cultured
podocytes
We have reported previously on the characterization of
immortalized heat-sensitive cultured mouse podocytes used
in this study.20–22 To ensure that these cells express the receptor
for ESPs, we performed immunostaining and Western blot
analysis. Both techniques demonstrated that podocytes used in
the current study express the erythropoietin receptor, forming
the rationale for further investigation (Figure 1).
Darbepoetin alfa protects cultured podocytes from apoptosis
induced by low-dose uv-C, TGF-b1 but is not protective
against puromycin aminonucleoside-induced apoptosis
EPO and other ESPs have been shown to be protective against
neuronal cell apoptosis induced by a variety of stimuli.4,8,23
We hypothesized that ESPs would be protective against
podocyte apoptosis, and we induced apoptosis in cultured
podocytes using ultraviolet-C (uv-C) irradiation, transform-
ing growth factor-b1 (TGF-b1), and puromycin aminonu-
cleoside (PA). Because protection against apoptosis in other
cell types typically requires pre-exposure to ESPs, darbe-
poetin alfa was first applied from 0 to 6 h before the induction of
apoptosis. Podocytes required a minimum of 3 h of pre-
exposure to darbepoetin alfa before a statistically significant
protective benefit was achieved (Figure 2a). Dose titration
experiments showed that exposing podocytes to darbepoetin
alfa 3 h before the induction of apoptosis significantly
reduced uv-C-induced apoptosis in a dose-dependent
manner (Figure 2b and c). Additionally, uv-C dose titration
experiments were performed which showed that darbepoetin
alfa protects against low-dose uv-C-induced apoptosis. In
contrast, darbepoetin alfa did not reduce necrosis induced by
high doses of uv-C (data not shown). Apoptosis was verified
further by Western blot analysis of caspase cleavage, as uv-C
irradiation is known to induce caspase cleavage (Figure 2d).24
Densitometry analysis of Western blots for caspase and the
caspase cleavage product showed that pre-exposure of
podocytes to darbepoetin alfa before uv-C irradiation results
in a substantial decrease in the ratio of total caspase to
caspase cleavage fragments from 75 to 40%.
DNA damage is the primary method by which uv-C
irradiation induces apoptosis.24,25 To ensure that pre-
exposure with darbepoetin alfa did not interfere with the
generation of DNA damage by uv-C, single-cell gel electro-
phoresis (Comet assay) was performed to quantify DNA
strand breaks. Our data showed that there was an equivalent
percentage of comet tails in control podocytes and darbe-
poetin alfa exposed podocytes, indicating that the amount of
DNA damage induced by uv-C was equivalent and that
darbepoetin alfa did not interfere with the generation of
DNA damage, the apoptotic trigger (Figure 2e).
TGF-b120,26–28 and PA20,29 have been shown to induce
podocyte apoptosis in vitro and in vivo. To determine if ESPs
universally protect podocytes against apoptotic triggers, we
induced apoptosis with TGF-b1 (5 ng/ml) and PA (10–50mg/ml)
after pre-exposing cells to darbepoetin alfa. Figure 3 shows
that darbepoetin alfa was protective against TGF-b1-induced
apoptosis. Without darbepoetin alfa, the rate of apoptosis
was 3.35% after 38 h of exposure to TGF-b1 versus 1.5% with
darbepoetin alfa pre-exposure (Po0.001) (Figure 3a). In
contrast, darbepoetin alfa had no impact on the quantity of
apoptosis induced by PA (Figure 3b).
Darbepoetin alfa does not induce proliferation of podocytes
Exposure of neuronal and endothelial cells in vitro to high
concentrations of EPO results in activation of the cell cycle
and proliferation.6,30 In contrast to these cells and other
glomerular cell types, podocytes typically do not proliferate
in response to injury. Thus, to determine if high dose
darbepoetin alfa exposure induces podocyte proliferation, we
utilized two approaches. First, we performed the 3-[4,5]
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Figure 1 | The EPO receptor is expressed on cultured mouse
podocytes. (a) Immunofluorescence staining performed on fixed
cells demonstrated that podocytes in culture express the EPO
receptor. (b) Negative control, omitting the primary antibody.
(c) Western blot analysis of enriched membrane and cytosolic protein
fractions. Lanes 1 and 3 are enriched membrane fractions as shown
by Naþ /Kþ -ATPase staining. Lanes 2 and 4 are cytosolic fractions
(negative controls) as shown by tubulin staining. Probing the
polyvinylidene difluoride membrane with an anti-EPO receptor
antibody identified a band at approximately 55 kDa, the expected
molecular weight of the EPO receptor in the membrane fractions of
the podocytes (lane 2) and renal fibroblasts (lane 4, positive control).
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dimethylthiazol-2,5-diphenyltetrazolium bromide (MTT) as-
say, which is an assay of cell viability and cell number.
Figure 4 shows that darbepoetin alfa had no effect on
proliferation of cultured podocytes grown under growth
permissive (i.e., undifferentiated and proliferating) and
restrictive (i.e., differentiated and quiescent) conditions.
Second, 5-bromo-2-deoxyuridine (BrdU) staining was uti-
lized as a marker for cell proliferation in proliferating
cultured podocytes after exposure to a wide range of
darbepoetin alfa doses (0–500 ng/ml). Immunostaining for
BrdU in podocytes did not show an increase in DNA
incorporation (data not shown). Taken together, these results
demonstrate that darbepoetin alfa does not alter or induce
podocyte proliferation in the mature, differentiated podocyte
in culture nor affect the rate of proliferation of the
undifferentiated cultured podocyte, and that any benefit on
survival were unlikely due to alterations in cell cycle.
Antiapoptotic effect of darbepoetin alfa requires intact
JAK2 and AKT pathways
After binding of ESPs to the EPO receptor, studies in non-
renal cells have shown that there is activation of a variety of
intracellular signaling pathways that result in a prosurvival
effect. Activation of JAK2/STAT pathway31 and the down-
stream of phosphoinositide-3 kinase/AKT pathway have been
shown to be critical to the anti-apoptotic effects of ESPs in
neuronal cells.4,32 We investigated the role of these crucial
pathways in podocytes by incubating cultured podocytes
with the JAK2 inhibitor, AG490, and with AKT inhibitors
before induction of apoptosis with uv-C. Our results show
P = 0.008 P < 0.001 for all comparisons
P = 0.016
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Figure 2 | Darbepoetin alfa protects podocytes from apoptosis induced by uv-C. (a) Darbepoetin alfa is protective against apoptosis
induced by uv-C irradiation after 3 h of pre-exposure. Heat-sensitive mouse podocytes were pretreated for 0–6 h with darbepoetin alfa
(100 ng/ml) and then exposed to uv-C irradiation (10 J/m2). Apoptosis was measured at 6 h by Hoechst 33342 staining. When darbepoetin alfa is
applied immediately after uv-C, at this dose of uv-C, there was 14.6% apoptosis which decreased to 11.8% with 1 h of pre-exposure, 9.58% after
2 h of pre-exposure, 7.2% after 3 h, and 6.6% after 6 h of pre-exposure to darbepoetin alfa. Statistically significant anti-apoptotic effects were
seen after 3 h of pre-exposure (P¼ 0.016 for 3 h pre-exposure compared with no pre-exposure and P¼ 0.008 for 6 h of pre-exposure, P¼ not
significant (NS) for other time points). (b) Darbepoetin alfa is protective against apoptosis induced by uv-C irradiation in a dose-dependent
manner. Cultured podocytes are pre-exposed for 3 h to darbepoetin alfa (varying doses 0–500 ng/ml) and then exposed to uv-C irradiation
(5 J/m2). Apoptosis was measured at 6 h by Hoechst staining. (Po0.001 for each dose compared to 0 ng/ml). (c) Representative Hoechst 33342
staining for vehicle and darbepoetin alfa (100 ng/ml) pre-exposed podocytes 6 h after uv-C irradiation showing more apoptotic nuclei (arrows)
in the vehicle-treated cells. (d) Uv-C irradiation primarily induces caspase-dependent apoptosis. Western blot analysis of total caspase 3 and
caspase 3 cleavage fragments shows decrease in caspase activation due to uv-C irradiation in darbepoetin alfa-exposed podocytes compared
to vehicle-exposed cells. (e) Darbepoetin alfa does not interfere with the generation of DNA damage by uv-C irradiation. Single-cell gel
electrophoresis (Comet assay) was performed to measure induction of DNA damage by uv-C irradiation. As expected, control podocytes
(column 1) and podocytes exposed to darbepoetin alfa, but not uv-C irradiation (column 2), have almost no detectable DNA damage at
baseline. After DNA damage is induced by uv-C, regardless of exposure to darbepoetin alfa (columns 3 and 4), podocytes develop equivalent
amounts of DNA damage. (P¼ 0.53 for comparison of uv-C and uv-Cþdarbepoetin alfa-treated cells).
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that the protective effect of darbepoetin alfa was abolished
after incubation with either AG490 (Figure 5a) or AKT IV
(Figure 5b) and AKT VII inhibitor (data not shown),
indicating that these pathways were critical in the regulation
of apoptosis in cultured podocytes and that the survival
benefits of darbepoetin alfa on cultured podocytes were
mediated in part through these pathways.
In vivo studies
The results shown above were performed in cultured
immortalized mouse podocytes. To validate these findings
in vivo, we utilized a mouse model of acute nephrotoxic
glomerulonephritis induced by intraperitoneal injection of
sheep anti-rabbit glomerular antibody, which is characterized
by podocyte apoptosis, dedifferentiation, and proliferation,
to test the hypothesis that darbepoetin alfa protects
podocytes from apoptosis in vivo. In this model, nephritic
mice develop azotemia, proteinuria, glomerulosclerosis, and
crescents composed of proliferating podocytes.22,33,34 Similar
to the in vitro study design, the mice in the experimental
groups were pretreated with vehicle (group 2, n¼ 6) or
darbepoetin alfa (group 3, n¼ 13) 24 h before induction of
the animal model. To insure that darbepoetin alfa itself had
no effect on podocytes in vivo, a control group (group 1,
n¼ 9) included animals injected with darbepoetin alfa in the
absence of the disease-inducing anti-glomerular antibody.
Mice were injected daily with darbepoetin alfa (25 ng/g) or
vehicle for 10 days. Nephritis was induced in the experi-
mental groups on days 2 and 3 with injection of the anti-
glomerular antibody. Immunostaining for sheep and mouse
IgG in darbepoetin alfa and vehicle-treated animals demon-
strated that anti-glomerular antibody deposition and the
autologous phase immune response were similar in both
groups, indicating that pretreatment with darbepoetin alfa
did not affect disease induction (data not shown). As shown
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Figure 3 | Darbepoetin alfa protects podocytes from apoptosis
induced by TGF-b1 but not puromycin aminonucleoside.
(a) Cultured podocytes are protected from apoptosis induced by
TGF-b1 by darbepoetin alfa. TGF-b1 (5 ng/ml) induced apoptosis in
podocytes was measured by Hoechst staining at 38 h. Apoptosis was
decreased from 3.3 to 1.5% (*Po0.001) with darbepoetin alfa
pre-exposure. (b) Darbepoetin alfa does not protect podocytes from
apoptosis induced by PA. PA (10, 30, and 50 mg/ml) induced cultured
podocyte apoptosis, measured by Hoechst staining at 48 h. Apoptosis
was not significantly reduced by pre-exposure to darbepoetin alfa.
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Figure 4 | Darbepoetin alfa does not induce proliferation of
cultured podocytes. (a) Undifferentiated and proliferating
podocytes. After 48 h of exposure to a range of doses of darbepoetin
alfa (0–500 ng/ml), the MTT assay was performed. Podocyte viability
and therefore cell number is equivalent in the exposed versus
unexposed, cultured, undifferentiated, and proliferating podocytes,
(P40.2 for every concentration compared to 0 ng/ml) demonstrating
that darbepoetin alfa exposure does not accelerate podocyte
proliferation. (b) Differentiated and quiescent podocytes. The MTT
assay was performed after 48 and 96 h of exposure to darbepoetin
alfa. These results demonstrate that darbepoetin alfa does not induce
quiescent podocytes to proliferate (P40.2 for every dose compared
to 0 ng/ml).
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Figure 5 | Inhibition of JAK2 or AKT phosphorylation eliminates
the protective effects of darbepoetin alfa on podocyte apoptosis
induced by uv-C. (a) Podocytes were incubated for 24 h with the
JAK2 inhibitor AG490 (20 mM) and then apoptosis was induced with
uv-C irradiation with or without darbepoetin alfa pre-exposure. In the
presence of AG490, the anti-apoptotic effect of darbepoetin alfa is
abolished with 6.92% apoptosis in the AG490þ uv-C-exposed
podocytes versus 5.07% in the AG490þdarbepoetin alfaþ
uv-C-exposed cells (P¼ 0.17). (b) Podocytes were incubated for
24–36 h with the AKT inhibitor, AKT IV, and then apoptosis was
induced by uv-C irradiation. In the presence of the AKT inhibitor,
there was similar amount of apoptosis in the darbepoetin alfa
exposed (10.2%) and vehicle-exposed podocytes (11.8%) (P¼ 0.66).
Controls for these experiments included podocytes incubated with
vehicle or inhibitor alone. Incubation with AKT IV but not AG490 or
AKT VII induces an increase in podocyte apoptosis at 32 h of 3.9%,
likely accounting for the higher rate of apoptosis in AKT IV exposed
podocytes.
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in Table 1, all mice treated with darbepoetin alfa had a
significant increase in hematocrit. Control animals from
group 1, which received darbepoetin alfa only, had an
increase in serum blood urea nitrogen (BUN) from 35 mg/dl
at baseline to 61.7 mg/dl at day 10 (Po0.001). Both of the
anti-glomerular antibody-treated experimental groups had
their BUN increase to 52 mg/dl. Although this was sig-
nificantly above the baseline BUN of 35 mg/dl (Po0.04), the
difference between nephritic mice given darbepoetin alfa or
vehicle was not statistically significant at day 10. Therefore
treatment with high-dose darbepoetin alfa did not improve
azotemia in this model.
Darbepoetin alfa improves glomerulosclerosis and reduces
proteinuria
All animals injected with anti-glomerular antibody developed
acute glomerulonephritis as determined by histological
examination by periodic acid-Schiff staining. Glomeruli were
analyzed for the presence of mesangial expansion, focal and
global glomerulosclerosis, and crescent formation by a
semiquantitative score based on percentage of glomerular
tuft involvement in the sclerotic process and the glomerulo-
sclerosis index was calculated.21,35 Characteristic glomeruli
from each group of animals are shown in Figure 6a–c. The
glomeruli from nephritic vehicle-treated animals (group 2)
had significantly more of the characteristic segmental
sclerosis than the darbepoetin alfa-treated animals (group 3),
and this was shown quantitatively by the higher glomer-
ulosclerotic index (P¼ 0.016) (Figure 6d). Darbepoetin
alfa treatment alone did not cause any significant glomerulo-
sclerosis in group 1 animals.
As shown in Figure 7, darbepoetin alfa treatment alone
(group 1) resulted in a minimal change in proteinuria from
baseline over the 10 days (11724%). In contrast, nephritic
animals had a significant increase in the percentage change in
urine protein excretion from baseline (446772%). Nephritic
animals treated with darbepoetin alfa had a significant
Table 1 | Baseline characteristics of control and treatment
groups
Experimental group 1 2 3
Antiglomerular antibody  + +
Darbepoetin +  +
Day 0 HCT 49.8 52.8 53.1
Day 10 HCT 68.7 46.2 66.1
Day 10 BUN 61.7 52.3 52.7
BUN, blood urea nitrogen; HCT, hematocrit.
The first group of animals was injected with darbepoetin alfa alone. This group had
a significant increase in their HCT from 49.8 to 68.7 at day 10 as well as a significant
increase in BUN from baseline 43 to 61.7 mg/dl at day 10 (Po0.001) probably due to
induction of renal vasoconstriction and a decrease in renal blood flow after 10 days
of treatment with high-dose darbepoetin alfa. Group 2 received the antiglomerular
antibody disease induction and vehicle treatment intraperitoneal. As expected, this
group had a decrease in HCT from baseline and an increase in BUN from 43 to
52.3 mg/dl. Group 3 received the antiglomerular antibody disease induction with
darbepoetin alfa treatment. These animals had an increase in HCT from 53 to 66.1 and
an increase in BUN from 43 to 52.7 mg/dl. Although the increases in BUN from
baseline to day 10 was significant in both groups 2 and 3 (Po0.04 for both), there was
no significant difference in BUN between these two groups at the end of the study.
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Figure 6 | Periodic Acid-Schiff (PAS) staining in mice with anti-glomerular antibody acute glomerulonephritis at day 10.
(a) Representative glomerulus from group 1 mouse treated with darbepoetin alfa alone showing normal mouse phenotype. (b) A glomerulus
characteristic of a nephritic, vehicle-treated mouse (group 2) showing segmental sclerosis typical of this model. (c) Mesangial expansion and
glomerular sclerosis is seen in both vehicle and darbepoetin alfa-treated animals but glomerular architecture is better preserved and there is
less sclerosis in the darbepoetin alfa-treated nephritic animals (group 3). (d) Glomerulosclerosis index. Kidneys from mice receiving darbepoetin
alfa alone had a very low degree of glomerular sclerosis as expected. Kidneys from nephritic, vehicle-treated mice (group 2) exhibited a
significantly greater disease severity than darbepoetin alfa-treated nephritic mice (group 3) as quantified by the glomerulosclerosis score
decreasing from 1.01 to 0.715 with darbepoetin alfa treatment (P¼ 0.016).
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blunting in their development of proteinuria with a change in
protein excretion of only 213753% (P¼ 0.017).
Darbepoetin alfa reduces apoptosis in vivo
To determine if ESPs have a similar anti-apoptotic effect
in vivo that we have demonstrated in vitro, we assessed podocyte
apoptosis following acute experimental glomerular injury by
terminal deoxy transferase uridin triphosphate nick end
labeling (TUNEL) staining. Characteristic glomeruli from
nephritic animals treated with vehicle or darbepoetin alfa are
shown in Figure 8. There was a significant decrease in
podocyte apoptosis in nephritic animals treatment with
darbepoetin alfa, with the number of TUNEL-positive cells
per glomerular cross-sectional area displayed in a podocyte
distribution decreasing from 0.1 to 0.05 with darbepoetin alfa
therapy (P¼ 0.0045). Additionally, WT-1 staining was
performed to quantify podocyte number. At this early time
point, we were not able to detect a significant change in
podocyte number by WT-1 staining, with 7.1270.12 WT-1-
positive cells on average per glomerulus in group 1 mice
compared with 7.0670.4 WT-1-positive cells per glomerulus
in group 2 and 7.1470.3 WT-1-positive cells per glomerulus
in group 3 mice. (P¼not significant (NS) for comparisons
between all groups.)
DISCUSSION
There is mounting evidence demonstrating that podocyte
apoptosis is an important determinant of proteinuria and
glomerulosclerosis in diabetic14–16 and non-diabetic renal
disease.17 Experimental and clinical studies have shown that a
reduction in podocyte number due to apoptosis or detach-
ment correlates with, and leads to, proteinuria and
glomerulosclerosis. Therefore, preventing or reducing podo-
cyte apoptosis should become an important therapeutic
target in the care of patients with glomerular disease. Despite
this, little progress has been made in augmenting existing
therapies with new prosurvival interventions. The current
study shows that darbepoetin alfa may serve to limit
podocyte loss through apoptosis, as our results demonstrate
that darbepoetin alfa reduced podocyte apoptosis in vitro and
in vivo.
Although the EPO receptor has been reported recently to
be expressed by podocytes in vivo,19 no reported data exists
showing its expression in cultured podocytes. Our data
indicates that cultured mouse podocytes do express the EPO
receptor, providing the rationale that ESPs might have
pleiotropic effects on this non-hematopoietic cell type. The
first major finding in the current study was that darbepoetin
alfa significantly reduced apoptosis in cultured podocytes in
response to certain forms of injury. Previous studies have
shown that darbepoetin alfa and other ESPs reduce apoptosis
in other renal and non-renal cells such as neurons and
P = 0.004
P < 0.001 P = 0.017
+
+Darbepoetin
Experimental
group
Antiglomerular
Antibody
+
+
–
–
1 2 3
500
400
300
200
100
Pe
rc
e
n
t c
ha
ng
e 
in
 p
ro
te
in
u
ria
0
Figure 7 | Darbepoetin alfa treatment decreases urine
proteinuria. Urine was collected for 12 h on day 10. The change in
protein excretion was calculated for each group of animals,
compared to baseline urine protein excretion. Darbepoetin alfa
treatment significantly decreased the rise in protein excretion that
occurs with acute glomerulonephritis in this model, from a 446772%
increase in vehicle-treated animals to 213752% increase in
darbepoetin alfa-treated animals (P¼ 0.017). Control animals treated
with 10 injections of darbepoetin alfa alone had a minimal change in
protein excretion of 11724% over the course of the study.
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Figure 8 | Darbepoetin alfa treatment decreases podocyte
apoptosis. (a) A representative glomerulus from a nephritic
vehicle-treated mouse (group 2) with a TUNEL-positive apoptotic
body in a podocyte distribution (white arrow) (b) A glomerulus from
a nephritic darbepoetin alfa-treated mouse (group 3) does not show
any TUNEL-positive cells in the glomerulus. A TUNEL-positive tubular
cell (black arrow) is a positive internal control. (c) There were
significantly fewer glomeruli with TUNEL-positive cells in the
darbepoetin alfa-treated animals. The number of glomerular
cross-sections with TUNEL-positive cells was decreased 50% from 0.1
to 0.05 with darbepoetin alfa treatment (P¼ 0.0045). Control animals
treated with darbepoetin alfa alone had minimal evidence of
apoptosis with 0.01 TUNEL-positive cells in a podocyte distribution
per glomerular cross-section.
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cardiomyocytes.4–8,10 Thus, the current study adds another
cell type to the non-hematopoietic benefits of ESPs.
The protective effect of ESPs requires pre-exposure in
non-renal cells, and this was also true in cultured podocytes.
Our data shows that darbepoetin alfa did not alter the
induction of apoptotic triggers as the quantity of DNA
damage following uv-C injury was similar in vehicle or
darbepoetin alfa-treated podocytes, suggesting that the
primary effect of ESPs is directly reducing apoptosis. This
led to the hypothesis that ESP treatment may improve the
podocyte’s ability to respond to apoptotic stimuli. Although
many of the hematopoietic pathways of cell survival may be
activated in podocytes, it is probably that there are podocyte-
specific pathways that are activated. One clue to potential
mechanisms is the fact that the prosurvival effects of ESPs on
podocytes are not universal. Our results showed that
darbepoetin alfa reduced apoptosis in response to low-dose
uv irradiation and TGF-b. Both uv-C24 and TGF-b26–28 cause
caspase-3-dependent apoptosis. In contrast, darbepoetin alfa
had no effect on podocyte apoptosis induced by puromycin
aminonucleoside, which we have shown previously to cause
apoptosis in a p53-dependent and in a caspase-3-indepen-
dent manner in podocytes.18
We next explored potential mechanisms that darbepoetin
alfa might afford a survival benefit in podocytes. Studies in
renal and non-renal cells suggested multiple signaling
pathways upstream of caspases are potentially activated by
ESPs, including the activation of JAK2, STAT5, nuclear
factor-kB, BclXL, PI3K, and then downstream phosphoryla-
tion of AKT.4 Our initial studies have shown that JAK2 and
AKT phosphorylation are critical and required for the
protective effects of ESPs in podocytes. Further studies are
underway to explore the redundancy of these pathways and
the activation of other survival pathways in podocytes in
response to stimulation from hematopoietic growth factors.
The use of immortalized mouse podocytes in culture has
substantially enhanced our understanding of podocyte
biology. However, to validate that the findings in culture
can be replicated in vivo, we used a well-described mouse
model of podocyte apoptosis. The second major finding of
the current study was that darbepoetin alfa significantly
reduces proteinuria, glomerulosclerosis, and podocyte
apoptosis. Although dexamethasone,18 insulin-like growth
factor,36 exogenous vascular endothelial growth factor,37 and
all-trans retinoic acid38 have been shown to reduce podocyte
apoptosis in vitro, only chronic apocynin therapy which
reduces nicotinamide adenine dinucleotide phosphate
oxidase-dependent reactive oxygen species production in the
db/db mouse model of diabetic nephropathy has been shown
to reduce podocyte apoptosis in vivo.39
We acknowledge that the exact identity of the cells
undergoing apoptosis in the experimental model was not
defined based on molecular markers, but rather on histologic
location. The rationale for this is that following apoptotic
forms of injury, podocytes in vivo have a marked reduction in
their characteristic markers such as nephrin, podocin, and
WT-1. Additionally, there is no known expression de novo
of a novel protein that can be used for double staining
purposes to identify that the cells undergoing apoptosis
(TUNEL-positive) are indeed podocytes.
We were not able to detect any improvement in azotemia
by the treatment with darbepoetin alfa. One explanation
might be that high-dose EPO therapy may have contributed
to a rise in BUN in the darbepoetin alfa-treated animals as
this has been shown to occur with EPO therapy due to
induction of renal vasoconstriction and a decline in renal
blood flow.40 This was clearly demonstrated in the control
animals receiving darbepoetin alfa alone (without the
induction of nephritis) who displayed significant increases
in BUN. Further studies evaluating the benefits of lower
doses of ESPs will be necessary to identify the minimum dose
required to provide an anti-apoptotic benefit without the
side effect of polycythemia.
Despite the beneficial effects of darbepoetin alfa on
preventing podocyte apoptosis, there were no differences in
podocyte number as quantified by WT-1 staining in the
experimental and control groups. One explanation is that
while the benefits of darbepoetin alfa are clearly on apoptosis,
other causes of reduced podocyte number, such as detach-
ment, may not have been affected. Second, WT-1 staining
which was used to identify podocytes is reduced following
podocyte de-differentiation that occurs in the animal model
used for this study. Finally, this model does have some
podocyte proliferation in response to injury, and this may have
masked the overall effect of podocyte apoptosis on podocyte
number. Importantly, our data shows that darbepoetin alfa
alone does not increase podocyte proliferation in vivo.
This study was terminated after 10 injections of darbe-
poetin alfa due to polycythemia, and therefore the long-term
benefits of darbepoetin alfa, especially at lower doses, on
glomerular disease has yet to be determined. As recently
reviewed,41 the results of clinical studies evaluating the effects
of ESP treatment on progression of chronic kidney disease
have been mixed, but overall suggest a beneficial effect of ESP
therapy on stabilizing or slowing progression of renal decline
in diabetics and non-diabetics, especially when treated early
in their disease process.42–44 These studies have primarily
focused on the beneficial effects of improved oxygen delivery
to the interstitium and decreased reactive oxygen species
production combined with the anti-apoptotic effects of ESPs
on the tubular cells to slow progression. However, our results
suggest another potential beneficial mechanism at the
glomerular level with prevention of podocyte apoptosis.
The requirement for ESP pretreatment does not decrease
clinical utility, as most diabetic and non-diabetic glomerular
diseases are not acute phenomenon and are characterized by
continuous injury. Additionally, the recent development of
non-hematopoietic forms of ESPs, such as carbamylated
EPO,40 have shown that the tissue-specific effect can be
maintained without excessive adverse hematopoiesis.
In summary, this study shows that darbepoetin
alfa reduces apoptosis in podocytes in vitro and in an
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experimental animal model. These effects are mediated in
part by JAK2/STAT and AKT pathways. Further studies are
ongoing to identify a dose-specific effect and the applicability
of this finding to human glomerular disease.
MATERIALS AND METHODS
Immortalized mouse podocytes
Experiments were performed with passage 10-22 growth restricted,
conditionally immortalized heat-sensitive mouse podocytes. To
generate these cells, H-2Kb-tsA58 transgenic mice were utilized.
These mice harbor interferon-g inducible promotor for expression
of the thermosensitive SV40 large T antigen. Glomeruli were isolated
from kidneys, and podocytes were isolated from glomerular
outgrowths by dilution cloning.20,22,45 Podocytes were identified
by confirming the presence of podocyte-specific proteins by
immunostaining.20,46
Cells are initially cultured under growth permission conditions
on collagen I-coated plates at 331C in the presence of interferon-g
(50 U/ml). To induce the development of the differentiated and
quiescent phenotype, mirroring the in vivo podocyte phenotype,
cells were switched to 371C without interferon-g for longer than 12
days, which results in expression of the podocyte-specific proteins.20
Cells were grown in Roswell Park Memorial Institute 1640 media
containing 9% fetal bovine serum (Summit Biotechnology, Ft
Collins, CO, USA), penicillin (100 U/ml), streptomycin (100 mg/ml),
sodium pyruvate (1 mmol/l), 4-(2-hydroxyethyl)-1-piperazineetha-
nesulfonic acid buffer (10 mmol/l), and sodium bicarbonate
(0.075%).
Immunostaining, membrane protein extraction, and
Western blotting
Immunoflourescent staining and Western blot analysis was per-
formed on differentiated podocytes. Podocytes were plated onto
collagen-coated glass coverslips, fixed in 2% paraformaldehyde and
4% sucrose, and then permeabilized in 0.3% Triton X-100 before
incubation overnight at 41C with rabbit polyclonal EPO receptor
antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA),
followed by a secondary biotinylated mouse anti-rabbit antibody
and Alexa-Fluor 594-conjugated streptavidin (Molecular Probes,
Eugene, OR, USA). Omitting the primary antibody was used as a
negative control.
Isolation of enriched membranous protein fractions was
performed by subcellular fractionation. Cells were lysed in 10 mM
Tris buffer (pH 7.5) containing 300 mM sucrose, 1 mM ethylenedia-
minetetraacetic acid (Sigma-Aldrich, St Louis, MO, USA), protease
inhibitors (Roche, Indianapolis, IN, USA), 50 mM NaF (Sigma),
1 mM Na-orthovanadate (Sigma) and homogenized by sonication.
The cell homogenate was centrifuged for 5 min at 800 g, 5 min at
2000 g, and then 20 min at 10 000 g. The supernatant was
further centrifuged for 60 min at 100 000 g resulting in a cytosolic
protein fraction and a membranous enriched fraction. Protein
concentration was determined by BCA protein assay kit (Pierce,
Rockford, IL, USA). Reduced protein samples were separated by
sodium dodecyl sulfate–polyacrylamide gel electrophoresis and
transferred to polyvinylidene difluoride membrane by electroblot-
ting. Membranes were incubated overnight at 41C with the following
primary antibodies: EPO receptor antibody (Abcam, Cambridge, MA,
USA), caspase 3 (Cell Signaling, Danvers, MA, USA) Naþ /Kþ -ATPase
(Abcam), and tubulin (Neomarkers, Fremont, CA, USA) then
incubated with enhanced chemiluminescence anti-rabbit IgG
horseradish peroxidase (GE Healthcare, Piscataway, NJ, USA) before
detection with enhanced chemiluminescence Western blotting
detection system.
In vitro experimental design
Apoptosis was induced in podocytes by three methods.
(i) uv-C irradiation. Uv-C irradiation (5–20 J/m2) was applied
to podocytes to induce apoptosis. Control cells were treated with
vehicle, and experimental cells were pre-exposed to darbepoetin alfa
(1–500 ng/ml) (Amgen, Thousand Oaks, CA, USA). These experi-
ments were repeated in three separate cell lines. For inhibitor
studies, podocytes were exposed for 24 h to the following inhibitors,
20 mM AG490 (Toronto Research Chemicals, North York, ON, USA),
1.25mM AKT IV (Calbiochem, San Diego, CA, USA), 10–25 mM AKT
VII (Calbiochem), or vehicle (dimethyl sulfoxide) and then
darbepoetin alfa for 3 h before uv-C irradiation.
(ii) PA. Apoptosis was induced by exposing podocytes to PA
(10–50 mg/ml) (Sigma) for 48 h, as we have reported previously.20
(iii) TGF-b1. Podocytes were exposed to 5 ng/ml of human
recombinant TGF-b1 (R&D Systems Inc, Minneapolis, MN, USA)
for 38 h.
Measuring apoptosis
Podocyte apoptosis was measured by staining with 0.0056% Hoechst
33342. Propidium Iodide staining was performed initially to
confirm that time points and doses used for the study were not
associated with significant necrosis. Apoptosis was defined by the
presence of chromatin condensation and formation of apoptotic
bodies. Morphologic analysis was performed on a minimum of 900
cells per experimental condition using inverted fluorescent micro-
scopy.20,47 All experiments were performed a minimum of three times.
Quantification of DNA damage
The Comet Flare assay (Trevigen, Gaithersburg, MD, USA) was
performed to quantify cleaved DNA fragments. Fifteen minutes after
uv-C irradiation, the cells were trypsinized and single-cell gel
electrophoresis (Comet assay)48,49 was performed according to the
manufacture’s instructions.
Assessment of cell proliferation
MTT assay. Both proliferating growth-permissive and growth-
restricted podocytes were utilized separately for this assay.
Equivalent numbers of cells were plated at 30% confluence and
then exposed to darbepoetin alfa (1–500 ng/ml). After 48 and 96 h,
the MTT assay was performed according to the manufacturer’s
instructions.
BrdU incorporation. Growth-permissive podocytes were plated
at 30% confluence and darbepoetin alfa added to the media
(1–500 ng/ml). After 48 h, the cells were labeled with BrdU labeling
media (GE Healthcare). After 4 h, the labeling media was removed
and the cells fixed in methanol/acetone. BrdU immunostaining was
performed using the cell proliferation labeling kit (GE Healthcare)
with diaminobenzidine (Fisher, Santa Clara, CA, USA) as the
chromogen.
In vivo studies: animal study and experimental design
An animal model of passive nephrotoxic glomerulonephritis was
induced in C57Bl/6 mice as reported previously by our
group.22,33,34,50 This model is characterized by podocyte injury,
de-differentiation, proliferation, apoptosis, and the development of
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proteinuria and glomerulosclerosis. This model is complement
independent and is not characterized by any significant amount of
neutrophil, T cell, or macrophage infiltration of the glomeruli. Mice
used for this experiment were housed according to the standardized
specific pathogen-free conditions in the University of Washington
Animal facility. The Animal Care Committee of the University of
Washington, Seattle reviewed and approved the experimental
protocol. Mice were divided into two groups: an experimental
group administered daily intraperitoneal darbepoetin alfa (25 ng/g)
(n¼ 13), or the control group administered vehicle (2.5% human
serum albumin, sodium phosphate monobasic monohydrate, sodium
phosphate dibasic monohydrate, and sodium chloride, pH 6.0)
(n¼ 6), starting 24 h before the induction of podocyte injury by
intraperitoneal injection of sheep anti-rabbit glomerular antibody
(0.5 ml/20 g) on two consecutive days. Darbepoetin alfa or vehicle
was administered daily for a total of 10 doses. An additional control
group of animals was injected daily with darbepoetin alfa only
(25 ng/g, n¼ 9) for a total of 10 days.
Blood was collected at days 0 and 10 by retro-orbital bleed, for
hematocrit and BUN measurement.22 Before killing, mice were
placed in metabolic urine collection cages for 12 h. The urine was
analyzed for protein concentration by the sulfosalicylic acid
method.51 To perform immunostaining, renal biopsies were fixed
in 10% neutral-buffered formalin, methyl Carnoy’s solution (60%
methanol, 30% chloroform, and 10% glacial acetic acid) or snap-
frozen and embedded in 22-oxacalcitriol.
Immunostaining
To ensure that the ESP treatment did not interfere with the
glomerular deposition of the anti-glomerular antibody used to
induce glomerulonephritis, frozen sections were fixed in methanol at
201C and then stained with fluorescein isothiocyanate-conjugated
antibody to sheep IgG (Cappel, Durham, NC, USA). The autologous
phase of the disease was assessed by immunostaining with the
fluorescein isothiocyanate-conjugated mouse IgG (Cappel). Apop-
tosis was measured using the TUNEL assay.52 Over 75 glomeruli per
cross-section were evaluated by a second masked observer and
determined to be TUNEL-positive if there was typical apoptotic
morphology and positive staining of the nuclei black. Indirect
immunoperoxidase staining was performed on methyl-carnoy fixed
tissue with antibody to WT-1 (Santa Cruz). Periodic acid-Schiff
staining was performed for the semiquantitative assessment of
glomerulosclerosis. Over 50 randomly selected glomeruli per section
were graded based on the percentage of glomerular tuft involved in
mesangial thickening or glomerular sclerosis as follows: 0¼ normal
glomerulus, 1p25%, 2¼ 25–50%, 3¼ 50–75%, and 4X75%.
Sclerotic index was calculated as described by Saito et al.35
Statistical analysis
All results are expressed as mean7s.e. Student t-test analyses were
performed using Microsoft Excel. Statistical significance was defined
as Po0.05.
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